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Abstract
Detection of microsatellite instabilities (MSI in colorectal cancer (CRC) patients aids in the diagnosis of Lynch
Syndrome. Early diagnosis allows the patient and their family to take preventative measures. Lynch Syndrome is a
hereditary disease caused by the loss-of-function germline mutations in genes that encode mismatch repair (MMR)
factors and is one of the most common cancer susceptibility syndromes. Individuals with Lynch syndrome have a
50-70% lifetime risk of colorectal cancer, 40-60% risk of endometrial cancer, and increased risk for several other
malignancies. Lynch Syndrome has led to CRC in patients beginning as early as 20 years old, with the average age of
affected individuals being 46 years old. Microsatellite instabilities was the first DNA marker available to identify a
hereditary CRC and led to the realization that MSI are a result of defects in the MMR system. Screening for Lynch
Syndrome is either carried out by polymerase chain reaction (PCR) of MSI or immunohistochemistry (IHC) testing.
There is some debate about which method is most effective, and this literature review will look more closely at this
debate about testing methodology. Regions of the MMR genes are also sequenced to look for mutations that may
help in diagnosis. There has been a steady increase in Lynch Syndrome tumor screening programs since 2000 and
institutions are rapidly adopting a universal screening approach to find the best methodology for testing and
interpreting results from CRC patients.

Screening for Lynch Syndrome

What is Lynch Syndrome
Lynch Syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is the
most common cause of hereditary colorectal (colon) cancer (CRC). Patients with Lynch
syndrome are susceptible to several other types of cancers such as uterine (endometrial),
stomach, liver, kidney, brain, and certain types of skin cancer. Lynch Syndrome is caused by
loss-of-function germline mutations in genes that code for the DNA mismatch repair
(MMR) factors. There are four genes that make up the MMR system: MLH1, MSH2, MSH6,
AND PMS2. The normal function of the MMR proteins is to proofread the nucleotide
sequence for potential base-base errors that occur during DNA synthesis. A defect in any of
the four genes can cause microsatellite instabilities (MSI). Microsatellites are short
repetitive sequences that are distributed throughout the human genome. MSI consists of a
gain or loss in repeat length depending on the defective gene from the MMR. The focus on
MSI in studies of CRC was aimed at Lynch Syndrome because of its inherited and unique
features. Patients with Lynch Syndrome develop tumors at early ages, often between 20
and 30 years old. These patients frequently have multiple tumors, including those in the
colon, rectum, endometrium, stomach, ovary, urinary tract, small intestine, and several
other sites. Although Lynch Syndrome accounts for up to 5% of CRCs, affected individuals
carry up to 80% lifetime risk for developing CRC and other cancers at an average age of 46.

Fig. 1 (left): The DNA mismatch repair
system is comprised of four definitive
genes, MLH1, MSH2, MSH6, AND PMS2.
These four genes search for a singlebase mismatches and repeat
mismatches that arise during DNA
synthesis.
Fig. 2 (below): Here is a comparison
between normal satellite replication
and abnormal caused by a mismatch
repair defect. Normal satellite
replication is shown on the left where
these repeated sequences are
replicated from the original strand of
DNA during synthesis. When there is a
MMR defect, as shown on the right, we
see a loss of repeat length and results in
a variance of allele size during DNA
synthesis.

Fig. 3 (above): This comparison shows the similarities and differences in 2 popular
revised screening methods used in diagnosing individuals with Lynch Syndrome, the
Revised Bethesda Guidelines and Amsterdam II Criteria.

In the 1990’s, research began on Lynch
syndrome. Research groups have
attempted to develop a universal
screening process to identify Lynch
syndrome in individuals within families
with clusters of CRC. In the late 1990’s,
the Amsterdam criteria and Bethesda
guidelines for screening and diagnosing
patients was developed along with many
other proposed guidelines. Despite
meeting the criteria and guidelines,
germline mutations are only detected in
up to 80% of Lynch syndrome instances.
Other studies have also shown that
guidelines may miss 6%-25% of mutation
carriers. Because universal screening has
not developed a complete set of
guidelines that fits every instance, many
clinicians make a major effort to
document detailed family histories in
order to identify families with Lynch
Syndrome. Once a patient is determined
to fit this criteria, the next step is to test
them for Lynch Syndrome.

Fig. 4 (above): To diagnose Lynch Syndrome, MMR genes are analyzed by PCR to detect point mutations and small insertiondeletion mutations within DNA sequences. The figure shows a comparison of the DNA sequences in cells from healthy tissue (top)
against the DNA sequence from the cells of a tumor from a biopsy (bottom). The red arrows indicate either point mutations or
small insertion-deletion mutations.

Fig. 5 (below): This is an example between the positive and negative IHC staining for a biopsied tumor for the MLH1 gene, one of
the four genes that makes up the MMR system. A positive stain indicates a defect in the MHL1 gene whereas a negative stain
indicates no defect in the MLH1 gene.

Testing for Lynch Syndrome
Once a patient has been determined by a clinician that they fit the criteria to be tested for Lynch
syndrome, they move on to the testing phase which gets them a few steps closer to a diagnosis.
There are two types of tests used for detecting Lynch syndrome—pathology tests and genetic
blood tests.
Pathology tests are tests that are performed on a tumor. When tumors are removed, most
hospitals store tissue samples for many years. If Lynch syndrome is suspected, special pathology
tests can be used to detect characteristics in tumors that may be caused by Lynch syndrome and
can identify which gene may be responsible for Lynch syndrome in the family. There are two
pathology tests used to evaluate the possibility of Lynch syndrome:
-Microsatellite instability (MSI) testing: Microsatellites are sequences of cellular DNA. In people
with Lynch syndrome, tumors will show changes in the microsatellites and these changes are called
microsatellite instability or MSI. Tumors with this instability are referred to as MSI-positive.
Approximately 95 percent of colorectal and uterine cancers in Lynch syndrome patients are MSIpositive.
-Immunohistochemistry (IHC) testing: Immunohistochemistry testing uses special dyes to stain
tissue samples in order to determine whether the proteins made by the Lynch syndrome genes are
present or absent. In patients with a Lynch syndrome gene mutation, the protein will be absent in
the tumor. IHC testing can help identify which of the four Lynch syndrome genes to test for.
The results of IHC or MSI tests can indicate that Lynch syndrome might be present, but they don’t
provide definitive information because some people can develop these gene mutations only in
their cancer cells. The suspicion of Lynch syndrome will be confirmed by blood tests.
Genetic tests are tests that look for changes in your genes that indicate that you have Lynch
syndrome. In order to undergo genetic testing, you will need to provide a blood sample. Genetic
professionals will then perform a special laboratory analysis on your blood to look at specific gene
mutations that cause Lynch syndrome.

Using MSI as a Predictor of Chemotherapy Response
Tests for MSI can be used to predict how a patient responds to adjuvant
chemotherapy, although this practice is controversial because many studies are still
in the clinical trial phase. In one study, MMR genes were identified in bacteria;
inactivating mutations created a mutant phenotype and allowed tolerance to DNAdamaging agents. A similar phenotype has been identified in mammalian cell lines.
The stable correction of MMR activity in cell lines restored the cytotoxic response
to several chemotherapeutic agents. This indicated that tumors with MSI might be
resistant to some chemotherapeutic regimens. Some studies have shown little to
no effect on survival times of MSI associated CRC while others have been successful
in their clinical trials. In one noted study by Fallik et al associated the inclusion of
the topoisomerase-I inhibitor, irinotecan, in the chemotherapeutic regimen
increased survival times of patients with MSI associated CRC. A similar finding has
been supported in another study by Bertagnolli et al. It is possible that a
combination of drugs without excessive immunotoxicity is best for patients with
MSI associated CRC. Patents with MSI associated CRC should continue to be
included in clinical trials until an appropriate treatment regimen is identified.
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